Pacira BioSciences, Inc. (NASDAQ:PCRX) Stock Position Cut by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC lessened its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 23.6% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,538 shares of the company’s stock after selling 1,400 shares during the period. Nisa Investment Advisors LLC’s holdings in Pacira BioSciences were worth $275,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Eaton Vance Management acquired a new stake in Pacira BioSciences in the 1st quarter valued at about $26,000. Amundi Pioneer Asset Management Inc. acquired a new stake in Pacira BioSciences in the 1st quarter valued at about $65,000. Shell Asset Management Co. acquired a new stake in Pacira BioSciences in the 1st quarter valued at about $99,000. Quantbot Technologies LP lifted its holdings in Pacira BioSciences by 182.4% in the 1st quarter. Quantbot Technologies LP now owns 1,765 shares of the company’s stock valued at $123,000 after acquiring an additional 1,140 shares during the last quarter. Finally, Russell Investments Group Ltd. acquired a new stake in Pacira BioSciences in the 1st quarter valued at about $171,000.

In related news, insider Max Reinhardt sold 421 shares of the stock in a transaction that occurred on Friday, July 2nd. The stock was sold at an average price of $59.76, for a total value of $25,158.96. The transaction was disclosed in a filing with the SEC, which is available at this link. 5.20% of the stock is owned by corporate insiders.

A number of equities research analysts have weighed in on PCRX shares. HC Wainwright cut their price target on shares of Pacira BioSciences from $86.00 to $84.00 and set a “buy” rating for the company in a report on Wednesday, August 4th. TheStreet raised shares of Pacira BioSciences from a “c+” rating to a “b” rating in a research note on Monday, August 9th. JPMorgan Chase & Co. raised shares of Pacira BioSciences from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $70.00 to $75.00 in a research note on Monday, July 26th. They noted that the move was a valuation call. Finally, Zacks Investment Research lowered shares of Pacira BioSciences from a “hold” rating to a “strong sell” rating and set a $48.00 price objective for the company. in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eight have assigned a buy rating to the company’s stock. According to, Pacira BioSciences has an average rating of “Buy” and an average target price of $76.85.

NASDAQ PCRX opened at $54.64 on Wednesday. The company has a 50 day simple moving average of $57.75 and a 200-day simple moving average of $62.43. The company has a debt-to-equity ratio of 0.47, a current ratio of 3.47 and a quick ratio of 3.18. The firm has a market capitalization of $2.43 billion, a price-to-earnings ratio of 13.97 and a beta of 1.07. Pacira BioSciences, Inc. has a 52-week low of $48.23 and a 52-week high of $80.00.

Pacira BioSciences (NASDAQ:PCRX) last posted its quarterly earnings results on Monday, August 2nd. The company reported $0.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.74 by $0.03. The business had revenue of $135.60 million during the quarter, compared to analyst estimates of $135.02 million. Pacira BioSciences had a net margin of 34.60% and a return on equity of 14.35%. The firm’s revenue was up 79.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.12 earnings per share. On average, analysts predict that Pacira BioSciences, Inc. will post 2 EPS for the current year.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which provide non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam.The company was founded in December 2006 and is headquartered in Parsippany, NJ.

See Also: What are high-yield dividend stocks?

Want to see what other hedge funds are holding PCRX? Visit to get the latest 13F filings and insider trades for Pacira BioSciences, Inc. (NASDAQ:PCRX).

Institutional Ownership by Quarter for Pacira BioSciences (NASDAQ:PCRX)

Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with's FREE daily email newsletter.